Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03732677 · ClinicalTrials.gov registry record · Phase 3
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
A Phase 3 study of Muscle-invasive Bladder Cancer, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 1,063
- Enrollment target
- 20
- Study locations
NCT03732677 is a Phase 3 study of Muscle-invasive Bladder Cancer that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 1,063 participants, below the 1,229-participant average among 10 other Muscle-invasive Bladder Cancer trials with a reported enrollment target (14% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT03732677, a Phase 3 study of Muscle-invasive Bladder Cancer, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,063 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment and Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer
Conditions Studied
Interventions
- DRUG Cisplatin
- DRUG Gemcitabine
- DRUG Durvalumab
Study Locations (20)
California
- Research Site - Los Angeles
- Research Site - Palo Alto
Illinois
- Research Site - Chicago
- Research Site - Geneva
Michigan
- Research Site - Ann Arbor
- Research Site - Detroit
New York
- Research Site - New York
- Research Site - Rochester
Other
- Research Site - Brisbane
- Research Site - Elizabeth Vale
Alabama
- Research Site - Birmingham
Connecticut
- Research Site - New Haven
Iowa
- Research Site - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,063 participants |
| Start Date | 2018-11-16 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03732677
The ClinicalTrials.gov registry entry for NCT03732677 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,063 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,229-participant average among 10 other Muscle-invasive Bladder Cancer trials with a reported enrollment target (14% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Muscle-invasive Bladder Cancer appearing as the primary indexed condition, and to 3 interventions - of which Cisplatin is the first listed.
NCT03732677 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Illinois, Michigan.
Frequently Asked Questions
What is clinical trial NCT03732677 about?
NCT03732677 is a clinical study titled "Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC". A Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment and Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer
What is the current status of trial NCT03732677?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,063 participants. The study started on 2018-11-16. Estimated completion is 2026-06-30.
What conditions does trial NCT03732677 study?
This clinical trial studies the following conditions: Muscle-invasive Bladder Cancer.
What interventions are being tested in trial NCT03732677?
The interventions under investigation include: Cisplatin (DRUG), Gemcitabine (DRUG), Durvalumab (DRUG).
Who is sponsoring clinical trial NCT03732677?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03732677 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Muscle-invasive Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy
ACTIVE NOT RECRUITING · Phase 3
-
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer
COMPLETED · Phase 3
-
Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma At High-Risk Recurrence
RECRUITING · Phase 2
-
Sample Collection for Ongoing Research and Product Evaluation Study
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.